Your browser doesn't support javascript.
loading
Clonal analyses of refractory testicular germ cell tumors.
Barrett, Michael T; Lenkiewicz, Elzbieta; Malasi, Smriti; Stanton, Melissa; Slack, James; Andrews, Paul; Pagliaro, Lance; Bryce, Alan H.
Afiliação
  • Barrett MT; Division of Hematology and Oncology, Mayo Clinic, Phoenix, Arizona, United States of America.
  • Lenkiewicz E; Department of Research, Mayo Clinic, Scottsdale, Arizona, United States of America.
  • Malasi S; Department of Research, Mayo Clinic, Scottsdale, Arizona, United States of America.
  • Stanton M; Department of Research, Mayo Clinic, Scottsdale, Arizona, United States of America.
  • Slack J; Division of Anatomic Pathology, Mayo Clinic, Scottsdale, Arizona, United States of America.
  • Andrews P; College of Medicine, Mayo Clinic, Phoenix, Arizona, United States of America.
  • Pagliaro L; College of Medicine, Mayo Clinic, Phoenix, Arizona, United States of America.
  • Bryce AH; College of Medicine, Mayo Clinic, Rochester, Minnesota, United States of America.
PLoS One ; 14(3): e0213815, 2019.
Article em En | MEDLINE | ID: mdl-30870501
ABSTRACT
Testicular germ cell tumors (TGCTs) are unique amongst solid tumors in terms of the high cure rates using chemotherapy for metastatic disease. Nevertheless, TGCTs still kill approximately 400 men per year, at a median age of 30 years, in the United States. This young age of mortality dramatically amplifies the impact of these deaths for the patients and their often young families. Furthermore the high cure rate makes it difficult to conduct further clinical trials of non curable disease. TGCTs are characterized by a marked aneuploidy and the presence of gain of chromosomal region 12p. Genomic testing may offer the ability to identify potentially lethal TGCTs at the time of initial diagnosis. However sequencing based studies have shown a paucity of somatic mutations in TGCT genomes including those that drive refractory disease. Furthermore these studies may be limited by genetic heterogeneity in primary tumors and the evolution of sub populations during disease progression. Herein we applied a systematic approach combining DNA content flow cytometry, whole genome copy number and whole exome sequence analyses to interrogate tumor heterogeneity in primary and metastatic refractory TGCTs. We identified both known and novel somatic copy number aberrations (12p, MDM2, and RHBDD1) and mutations (XRCC2, PIK3CA, RITA1) including candidate markers for platinum resistance that were present in a primary tumor of mixed histology and that remained after tandem autologous stem cell transplant.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Testiculares / Biomarcadores Tumorais / Genoma Humano / Cisplatino / Células Clonais / Neoplasias Embrionárias de Células Germinativas / Resistencia a Medicamentos Antineoplásicos Limite: Humans / Male Idioma: En Revista: PLoS One Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Testiculares / Biomarcadores Tumorais / Genoma Humano / Cisplatino / Células Clonais / Neoplasias Embrionárias de Células Germinativas / Resistencia a Medicamentos Antineoplásicos Limite: Humans / Male Idioma: En Revista: PLoS One Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos